Cormorant Asset, an investment manager, led a $125m Series A funding round in Chroma Medicine, a developer of biotechnology. Additional investors include Atlas Venture, Newpath Partners, Sofinnova Partners, Casdin Capital, Janus Henderson Investors, Omega Funds, T. Rowe Price and Wellington Management. "Epigenetic editing is the next frontier in genomic medicine with the potential to transform the treatment of genetically driven diseases. By harnessing nature's innate mechanism to modulate gene expression, we can durably and precisely control gene expression without fundamentally changing or cutting the underlying DNA sequence. Supported by world-class founders and investors, the Chroma team is committed to deliver on the promise of this exciting platform," Catherine Stehman-Breen, Chroma Medicine CEO.